RECENT NEWS

Visit the WFH News page to find out more about the events and developments that are making a difference today.

HA logo

Takeda joins WFH Humanitarian Aid Program

The World Federation of Hemophilia (WFH) is proud to announce that Takeda has joined the WFH Humanitarian Aid Program with a five-year product donation of factor and bypassing agents. This commitment represents a new milestone for Takeda’s collaboration with the WFH.

Also available in: Français Español

The World Federation of Hemophilia (WFH) is proud to announce that Takeda has joined the WFH Humanitarian Aid Program with a five-year product donation of factor and bypassing agents. This commitment represents a new milestone for Takeda’s collaboration with the WFH. Takeda has supported many WFH programs in the last 30 years, including the World Bleeding Disorder Registry (WBDR) and the Global Alliance for Progress (GAP) Program—the latter since its launch in 2003. With this new commitment, Takeda becomes a WFH Humanitarian Aid Program “Contributor” level sponsor and will provide 15 million IUs of FVIII and 5 million IUs of bypassing agent per year for the next five-years to the WFH.

The WFH Humanitarian Aid Program improves lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care.

“Takeda has collaborated with the WFH for over 30 years, playing an important role in several of our programs, including the Global Alliance for Progress (GAP) Program and the World Bleeding Disorder Registry (WBDR),” says Alain Baumann, CEO of the WFH. “We are thankful that Takeda has now extended their support to the WFH Humanitarian Aid Program. This will allow the WFH to do even more to support bleeding disorders communities in need around the world.”

Julie Kim—President of the Plasma Derived Therapies Business Unit at Takeda—had this to say about the important milestone in the Takeda’s collaboration with the WFH: “At Takeda we recognize the need to advance the standard of care for those living with a rare bleeding disorder, as well as the importance of tackling disparities in access to treatment worldwide. This five-year product donation aims to help the WFH in improving access to treatment, including prophylaxis to protect joint health. We are pleased to be able to continue collaborating with the WFH on their flagship advocacy and data collection programs, supporting our commitment to achieve a world without bleeds.”

About the WFH Humanitarian Aid Program

The WFH Humanitarian Aid Program improves the lack of access to care and treatment by providing much-needed support for people with inherited bleeding disorders in developing countries. By providing patients with a more predictable and sustainable flow of humanitarian aid donations, the WFH Humanitarian Aid Program makes it possible for patients to receive consistent and reliable access to treatment and care. None of this would be possible without the generous support of Sanofi Genzyme and Sobi, our Founding Visionary Contributors; Bayer and Roche, our Visionary Contributors; Grifols, our Leadership Contributor; and our Contributors, CSL Behring and Takeda.  To learn more about the WFH Humanitarian Aid Program, visit www.treatmentforall.org.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.